1. Quali differenze in rapporto al sesso nella monoinfezione HCV PITER cohort data Loreta Kondili Istituto Superiore di Sanità

2. Enrollmet in the PITER cohort as by October 2015 7492 patients enrolled from 80 clinical centers PITER is a well rapresentative sample of patients in care in Italy.

3. Web- Based Data Collection

4. Distribution of patients enrolled in by gender Women 3317 (44%) Mean age 62+-12 years Men 4175 (56%) Mean age 58+-12 years

5. Distribution of patients enrolled in by gender and age groups

6. Body Max Index according to gender Men

7. Fibrosis Distribution according to gender and age groups

8. HCV Genotypes Distribution according to gender Overall Genotype Distribution Gt1 = 65%; Gt2=15%;Gt3=11%;Gt4=6% Other 1%

9. Distribution of HCV Genotypes in patients with Clinical cirrhosis

10. Coinfections Women 130/3317= 4% 1869 N.D. HIV status 130/1656 =8% HBsAg 26/2408 =1% (823 ND HBsAg positivity) Men 319/4175 =7.6% 1869 N.D. HIV status 319/2306 =14% Positivity 26/3079 =2% (960 ND HBsAg positivity) HIV Positivity

11. Previous Therapeutic history according to gender Naive: 3655pt: Men: 1914 Women: 1741 Experienced:3653pt Men 2159 Women 1494

12. Distribution of Fibrosis in treatment experienced patients Men

13. Distribution of Fibrosis in Naive patients F0-1 51% F2 14% F0-F1:51% F2:14% F3:10% F4:23% Women F0-F1:42% F2:13% F3:11% F4:34% Men

14. Factors correlating with cirrhosis Factors N 6831 OR Univariate CI 95% OR Adjusted CI 95% Mean Age59+-131.031.025-1.03411-1 Gender F vs M3034/37970.60.5-0.70.70.6-0.8 Previous Alcohol use yes/No use1435/43111.91.7-2.21.61.3-2 Actual Alcohol use/no use1083/43110.70.6-0.80.60.5-0.8 BMI >= 25 vs BMI<252606/34701.41.2-1.51.41.2-1.6 BM I>= 30 vs BMI<25726/34701.81.5-2.121.6-2.6 HCV Genotype 1 vs 23996/10131.71.4-2.01.41.1-1.7 3 vs 2655/101321.6-2.41.51.2-2.1 4 vs 2446/10131.41.1-1.81.20.7-1.6 Others vs 298/10131.30.8-21.40.7-2.5 Diabetes vs Non Diabetes913/59182.92.5-3.31.71.4-2.1 >2 times Increased Gamma GT vs NR965/23134.43.7-5.12.52-3.1 >2 times Increased ALT vs NR1748/26043.32.9-3.80.70.5-0.9 >2 times Increased AST vs NR1647/26367.36.4-8.44.23.1-5.6 PLT: 50 000-100 000 vs >150 0001250/37646.55.7-7.523.518.8-29.4 PLT: 100 000 -150 000 vs>150 0001440/376434.428.5-41.64.84.1-5.6

15. Comorbidity according to Gender Gender Comorbidity Male N (4174) %Female N (3317) % Autoimune1032.41885.6* Cardiovascular125129.9115134.7* Diabetes61614.739411.8 Haematologic2145.11564.7 Neurologic1433.41133.4 Osteoarticolar1303.134510.4* Psychiatric25363279.8 Renal1573.7892.6 Tumours1503.62377.1* Other71617.147514.3

16. Conclusions Compared to men patients enrolled Women account for 46 % of overall patients and have a mean age one decade older. Genotype 1 and 2 are more frequently present overall and in women with cirrhosis F0-F1 is significantly more prevalent in both age groups below and over 60 years of age Women naive and experienced to previous antiviral therapies have more frequently fibrosis F0-F1 than F4 cirrhosis Women gender is inversly correlated to liver cirrhosis ; Women with cirrhosis are older Women have more frequent cardiovascular disease, osteoarticolar disease and tuomors.